Skip to main content

' Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema) s.c. in doses 2.4/2.4 mg and 1.0/1.0 mg once weekly versus semaglutide 2.4 mg and 1.0 mg, cagrilintide 2.4 mg and placebo in participants with type 2 diabetes inadequately controlled on metformin with or without an SGLT2 inhibitor.

Open
  • Protocol code: NN9388-4896
  • EudraCT code: No aplica
  • Research group: Diabetes and Metabolism
  • Service: Endocrinology
  • Principal investigator:  Ciudin Mihai, Andreea
  • Pathology: Malalties endocrines, nutricionals i metabòliques
  • Phase: Fase III
  • Status: Recruiting volunteers